Objective: To compare the effectiveness of pharmacists dosing warfarin for in-patients, in comparison to that of junior doctors, in order to establish the value of a pharmacist-controlled in-patient anti-coagulation service.
Setting: Brighton and Sussex University Hospitals NHS Trust (BSUH).
Method: Two wards at Brighton General Hospital were under pharmacist-control of warfarin dosing and three wards remained under the care of doctors. Data was collected for 11 months and a total of 33 patients were recruited into each arm.
Results: Pharmacists prescribed more appropriate loading and maintenance doses (according to the Trust's Prescribing Guidelines) compared to doctors. This resulted in more patients reaching their target INR sooner. Documentation of indication, duration of treatment and target INR was also much improved compared to medical staff. However, more patients (73%) in the doctors' group were within range on discharge and at the out-patient clinic (79%), compared to the pharmacists (68% & 61% respectively). This could not be explained entirely. Significantly fewer patients dosed by pharmacists had episodes of over or under anti-coagulation (91% vs 67%) and fewer INR tests were requested (2.3/patient/week) compared to those dosed by doctors (2.7). Patients under the control of pharmacists also had fewer adverse events (6% vs 12%). One major GI bleed occurred in the doctors' group.
Conclusion: Pharmacist dosing of warfarin for in-patients had a beneficial effect on most aspects of anti- coagulation control. This study therefore provides further evidence to support the extended role pharmacists can play with the benefit of reducing risk, junior doctors' hours and improving patient care.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1023/b:phar.0000035885.00408.9e | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
[Analysis of 41 cases of myocardial infarction in children with coronary artery lesion after Kawasaki disease].
Zhonghua Er Ke Za Zhi
January 2025
Pediatric Heart Center, Children's Hospital of Fudan University, National Children's Medical Center, Shanghai, 201102 China.
To analyze the clinical characteristics,diagnosis and treatment of pediatric myocardial infarction (MI) patients with coronary artery lesions (CAL) after Kawasaki disease (KD). Clinical data including baseline characteristics, KD and CAL information, clinical symptoms at MI onset, electrocardiogram (ECG) and imaging findings, MI treatment, and clinical outcomes of 41 MI patients with CAL after KD admitted to the Children's Hospital of Fudan University from January 2017 to August 2024 were analyzed retrospectively. (1) Demographic characteristics: a total of 41 patients were included (36 males and 5 females).
View Article and Find Full Text PDFA Mysterious Cause of Coagulopathy With Bleeding Diathesis.
Cureus
December 2024
Department of Internal Medicine IV, Hospital Professor Doutor Fernando Fonseca, Amadora, PRT.
Vitamin K is essential to produce functional vitamin K-dependent coagulation factors (prothrombin, factors VII, IX, and X). Vitamin K antagonists inhibit the normal activation of these factors, leading to bleeding manifestations of variable severity. Long-acting vitamin K antagonists or superwarfarins were developed as rodenticides and have a significantly longer half-life and greater potency when compared to warfarin.
View Article and Find Full Text PDFFor Atrial Fibrillation, DOACs Outperform Warfarin in Patients with Reduced Kidney Function.
J Am Board Fam Med
January 2025
From the Madigan Army Medical Center Family Medicine Residency, Tacoma, WA (RP, JC, AH).
At standard doses, direct oral anticoagulants (DOACs) were associated with a reduced risk of systemic embolism and intracranial hemorrhage (ICH) when compared with warfarin, with a greater derived benefit at lower creatinine clearance (CrCl-down to 25 mL/min). Lower doses of DOACs were associated with increased overall mortality without a significant decrease in ICH and incident bleeding when compared with standard dose DOACs and warfarin, across all CrCl down to 25 mL/min..
View Article and Find Full Text PDFChange surface regression for nonlinear subgroup identification with application to warfarin pharmacogenomics data.
Biometrics
January 2025
Department of Statistics and Data Science, National University of Singapore, Singapore 117546, Singapore.
Pharmacogenomics stands as a pivotal driver toward personalized medicine, aiming to optimize drug efficacy while minimizing adverse effects by uncovering the impact of genetic variations on inter-individual outcome variability. Despite its promise, the intricate landscape of drug metabolism introduces complexity, where the correlation between drug response and genes can be shaped by numerous nongenetic factors, often exhibiting heterogeneity across diverse subpopulations. This challenge is particularly pronounced in datasets such as the International Warfarin Pharmacogenetic Consortium (IWPC), which encompasses diverse patient information from multiple nations.
View Article and Find Full Text PDFEffectiveness and Safety of Dose-Specific DOACs in Patients With Atrial Fibrillation: A Systematic Review and Network Meta-Analysis.
Cardiovasc Ther
January 2025
College of Pharmacy and Institute of Pharmaceutical Science and Technology, Hanyang University, Ansan-si, Gyeonggi-do, Republic of Korea.
Dose adjustments of direct-acting oral anticoagulants (DOACs) for atrial fibrillation are based on pivotal clinical trials assessing their effectiveness and safety in controlled settings. However, the appropriateness of these dosing strategies in real-world practice is uncertain. The purpose of this study is to compare the effectiveness and safety of dose-specific DOACs with those of warfarin.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!